In conclusion, the emergence of DM/PM and a specific subset of such diseases as the antisynthetase syndrome seem to be associated with the use of anti-TNF-α agents, especially in patients with chronic inflammatory diseases (mainly RA but also AS and Crohn's disease) and with positive autoantibodies before therapy initiation. Here, TNF is linked to antisynthetase syndrome.